Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb trial of adamgammadex sodium for reversal of deep rocuronium-induced neuromuscular blockade
ChiCTR2100047748Phase 2Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of adamgammadex in reversal of nondepolarizing neuromuscular blockade (4 arms), sponsored by Renji Hospital. Primary endpoint: Time from study drug administration to TOF ratio recovery to 0.9. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
adamgammadex
03
Conditions
reversal of nondepolarizing neuromuscular blockade
Beyond the preview
Go deeper on ChiCTR2100047748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047748.